Toshiaki Iwase
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Toshiaki Iwase has a total of 172 co-authors. Here are the top co-authors by number of shared publications:
- Naoto T. Ueno
University of Hawaiʻi Cancer Center Inflammatory Breast Cancer Clinic and Research Program, Honolulu, USA
39 shared publications - Xiaoping Wang
Cancer Biology Program, University of Hawai’i Cancer Center, Honolulu, USA
28 shared publications - Bora Lim
Department of Breast Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA
27 shared publications - Debu Tripathy
Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
27 shared publications - Savitri Krishnamurthy
Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
26 shared publications - Yu Shen
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
26 shared publications
Latest Publications
- Open Access
- 1 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (18) , eadu0031
Pervasive enhanced transcription in inflammatory breast cancer tumors and PBMCs impacts RNA splicing and intronic RNAs in plasma
Inflammatory breast cancer (IBC), an aggressive and lethal breast cancer subtype, lacks unequivocal genomic differences or robust biomarkers that differentiate it from non-IBC. Here, TGIRT-seq revealed myriad differences in tumors, PBMC, and plasma RNAs that distinguished IBC patients from non-IBC patients and healthy donors across different tested breast cancer subtypes. By mapping reads to genome and transcriptome reference sequences and quantitating intron-to-exon read depth ratios (IDRs), we developed methods for parallel analysis of transcriptional and posttranscriptional gene regulation. This analysis identified numerous protein-coding genes in IBC patient tumors and PBMCs with high IDRs, suggesting rate-limiting RNA splicing that decreases mRNA production. Mirroring gene expression differences in tumors and PBMCs, overrepresented protein-coding gene RNAs in IBC patient plasma were largely intron RNA fragments, while those in non-IBC patient and healthy donor plasma were largely mRNA fragments. Our findings provide insights into IBC and should enable monitoring disease progression by liquid biopsy.
- 1 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (18) , eadu0031
Open AccessPervasive enhanced transcription in inflammatory breast cancer tumors and PBMCs impacts RNA splicing and intronic RNAs in plasma
Inflammatory breast cancer (IBC), an aggressive and lethal breast cancer subtype, lacks unequivocal genomic differences or robust biomarkers that differentiate it from non-IBC. Here, TGIRT-seq revealed myriad differences in tumors, PBMC, and plasma RNAs that distinguished IBC patients from non-IBC patients and healthy donors across different tested breast cancer subtypes. By mapping reads to genome and transcriptome reference sequences and quantitating intron-to-exon read depth ratios (IDRs), we developed methods for parallel analysis of transcriptional and posttranscriptional gene regulation. This analysis identified numerous protein-coding genes in IBC patient tumors and PBMCs with high IDRs, suggesting rate-limiting RNA splicing that decreases mRNA production. Mirroring gene expression differences in tumors and PBMCs, overrepresented protein-coding gene RNAs in IBC patient plasma were largely intron RNA fragments, while those in non-IBC patient and healthy donor plasma were largely mRNA fragments. Our findings provide insights into IBC and should enable monitoring disease progression by liquid biopsy.
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy
Supplementary Figure 4. Progression-free survival and overall survival stratified by PD-L1 IHC status (n = 32).
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy
Supplementary Figure 4. Progression-free survival and overall survival stratified by PD-L1 IHC status (n = 32).
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy
Supplementary Table S2. Induction chemotherapy regimen before the maintenance therapy.
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy
Supplementary Table S2. Induction chemotherapy regimen before the maintenance therapy.
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy
Supplementary Figure 7. T-cell activation observed as changes in peripheral blood T-cell receptor repertoire after 2 courses of pembrolizumab maintenance therapy. The boxplot shows the interquartile range with whiskers extending up to 1.5 times the interquartile range.
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy
Supplementary Figure 7. T-cell activation observed as changes in peripheral blood T-cell receptor repertoire after 2 courses of pembrolizumab maintenance therapy. The boxplot shows the interquartile range with whiskers extending up to 1.5 times the interquartile range.
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy
Supplementary Figure 1. CONSORT diagram.
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy
Supplementary Figure 1. CONSORT diagram.
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy
Supplementary Table S2. Induction chemotherapy regimen before the maintenance therapy.
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy
Supplementary Table S2. Induction chemotherapy regimen before the maintenance therapy.
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy
Supplementary Figure 5. Significant decreases in T-cell exhaustion markers were associated only with patients who responded to pembrolizumab maintenance therapy. The boxplot shows the interquartile range with whiskers extending up to 1.5 times the interquartile range
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy
Supplementary Figure 5. Significant decreases in T-cell exhaustion markers were associated only with patients who responded to pembrolizumab maintenance therapy. The boxplot shows the interquartile range with whiskers extending up to 1.5 times the interquartile range
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy
Supplementary Figure 3. Overall survival duration stratified by the response to prior chemotherapy.
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy
Supplementary Figure 3. Overall survival duration stratified by the response to prior chemotherapy.
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy
Supplementary Figure 6. Progression-free survival and overall survival stratified by clonality in patients with PD-L1–negative tumors per IHC analysis (N = 32).
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy
Supplementary Figure 6. Progression-free survival and overall survival stratified by clonality in patients with PD-L1–negative tumors per IHC analysis (N = 32).